Cat # changed from RSCYK111R to YK111
Competitive ELISA, Immobilized antibody
Plasma-EDTA, Plasma-Heparin, Plasma-Citrate
At ambient temperature. Upon receipt, store the product at the temperature recommended below.
Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
CV = 4.56 - 7.82
CV = 3.16 - 7.59
Rat plasma A - 95,72%
Rat plasma B - 92,34%
Glicentin is a 69-amino-acid peptide containing glucagon and oxyntomodulin sequences in the molecule. It is
suggested that glicentin and oxyntomodulin are produced in the intestinal L-cells and glucagon in A-cells
in the pancreas, these peptides are derived from a common precursor by two different tissue-specific processing
pathways. In 1983, the amino acid sequence of human glicentin was deduced by Bell et al. from the genomic
sequence of human preproglucagon. Glicentin is a major form of gut glucagon-like immunoreactants (Gut GLIs).
In mammalian small intestine, proglucagon is processed into glicentin, oxyntomodulin, and glucagon -like peptide
1(GLP-1) and glucagon -like peptide 2 (GLP-2). GLP-1(7-37) and GLP-1(7-36)amide have been isolated from
the intestine and pancreas. It has been known that the GLP-1 sequence is well conserved between species in all
mammals studied. Using synthetic peptides, several investigators have demonstrated that in contrast to GLP-1 (1-37), truncated GLP-1(7-36)amide and GLP-1(7-37) have several physiological effects. However, the physiological role of glicentin, a major gut glucagon, is still unclear. It has been known that the circulating level of plasma glicentin-like peptides increases significantly nutrient ingestion. Yanaihara institute Inc. has succeeded in developing a specific and convenient EIA kit for determination of rat glicentin in plasma.